Details of the Drug

General Information of Drug (ID: DM652O6)

Drug Name

Livoletide

Synonyms

AZP-531; AZP 531; UNII-9VHD7J6363; 9VHD7J6363; 1088543-62-7; 3-((3S,6S,9S,12S,15S,18S,21S,26aS)-6-((1H-imidazol-5-yl)methyl)-9,18-bis(3-amino-3-oxopropyl)-12-(3-guanidinopropyl)-21-(hydroxymethyl)-15-isopropyl-1,4,7,10,13,16,19,22-octaoxohexacosahydropyrrolo[1,2-a][1,4,7,10,13,16,19,22]octaazacyclotetracosin-3-yl)propanoic acid; AZP531; CHEMBL2029605; GTPL10884; Cyclo(des-acyl ghrelin(6-13)); DB15188; Q27896244; 3-((3S,6S,9S,12S,15S,18S,21S,24S)-6,15-Bis(3-amino-3-oxo-propyl)-12-(3-guanidinopropyl)-3-(hydroxymethyl)-18-(1H-imidazol-5-ylmethyl)-9-isopropyl-2,5,8,11,14,17,20,23-octaoxo-1,4,7,10,13,16,19,22-octazabicyclo(22.3.0)heptacosan-21-yl)propanoic acid; Cyclo(L-arginyl-L-valyl-L-glutaminyl-L-seryl-L-prolyl-L-alpha-glutamyl-L-histidyl-L-glutaminyl)

Indication

Disease Entry	ICD 11	Status	REF
Hyperphagia	MG43.9	Phase 2/3	[1]
Prader-Willi syndrome	LD90.3	Phase 2/3	[1]
------------------------------------------------------------------------------------

Drug Type

Peptide

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C40H63N15O13
Canonical SMILES: CC(C)C1C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCC(=O)N)CC3=CN=CN3)CCC(=O)O)CO)CCC(=O)N
InChI: 1S/C40H63N15O13/c1-19(2)31-38(67)51-23(8-11-29(42)58)34(63)53-26(17-56)39(68)55-14-4-6-27(55)37(66)50-24(9-12-30(59)60)33(62)52-25(15-20-16-45-18-47-20)36(65)49-22(7-10-28(41)57)32(61)48-21(35(64)54-31)5-3-13-46-40(43)44/h16,18-19,21-27,31,56H,3-15,17H2,1-2H3,(H2,41,57)(H2,42,58)(H,45,47)(H,48,61)(H,49,65)(H,50,66)(H,51,67)(H,52,62)(H,53,63)(H,54,64)(H,59,60)(H4,43,44,46)/t21-,22-,23-,24-,25-,26-,27-,31-/m0/s1
InChIKey: JXPWLIYXIWGWSA-CLBRJLNISA-N

Cross-matching ID

PubChem CID: 57341282
CAS Number: 1088543-62-7
TTD ID: DU0K2R

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT03790865) Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome (ZEPHYR). U.S. National Institutes of Health.